Ken Griffin: United Therapeutics UTHR Historial de posiciones en acciones
Comprado
Mantenidas
Vendido
| Trimestre | Valor de mercado | Estado | Acciones |
Cambio en la posición | Valor operado | Peso en el portafolio | Puesto en el portafolio | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 503 M | Compra |
928,464
+623,772
| +205% | +USD 323 M | 0.06% | 239 |
|
|
2026
Q2 | USD 165 M | Venta |
304,692
-55,951
| -16% | -USD 31.5 M | 0.02% | 647 |
|
|
2026
Q1 | USD 214 M | Compra |
360,643
+173,479
| +93% | +USD 86.4 M | 0.03% | 433 |
|
|
2025
Q4 | USD 91.2 M | Venta |
187,164
-86,818
| -32% | -USD 40.4 M | 0.01% | 928 |
|
|
2025
Q3 | USD 115 M | Compra |
273,982
+132,971
| +94% | +USD 44.7 M | 0.02% | 743 |
|
|
2025
Q2 | USD 40.5 M | Compra |
141,011
+104,827
| +290% | +USD 31.3 M | 0.01% | 1406 |
|
|
2025
Q1 | USD 11.2 M | Compra |
36,184
+15,846
| +78% | +USD 5.43 M | ﹤0.01% | 2706 |
|
|
2024
Q4 | USD 7.18 M | Compra |
+20,338
| Nuevas | +USD 7.48 M | ﹤0.01% | 3406 |
|
|
2024
Q2 | – | Venta |
-719,311
| Cerradas | -USD 190 M | – | 15475 |
|
|
2024
Q1 | USD 165 M | Compra |
719,311
+641,414
| +823% | +USD 145 M | 0.03% | 445 |
|
|
2023
Q4 | USD 17.1 M | Compra |
77,897
+56,825
| +270% | +USD 13.1 M | ﹤0.01% | 2169 |
|
|
2023
Q3 | USD 4.76 M | Venta |
21,072
-22,252
| -51% | -USD 5.13 M | ﹤0.01% | 3726 |
|
|
2023
Q2 | USD 9.6 M | Venta |
43,324
-10,776
| -20% | -USD 2.39 M | ﹤0.01% | 2735 |
|
|
2023
Q1 | USD 12.1 M | Venta |
54,100
-270,831
| -83% | -USD 66.8 M | ﹤0.01% | 2553 |
|
|
2022
Q4 | USD 90.4 M | Venta |
324,931
-289,581
| -47% | -USD 73.1 M | 0.02% | 701 |
|
|
2022
Q3 | USD 129 M | Compra |
614,512
+555,159
| +935% | +USD 124 M | 0.03% | 484 |
|
|
2022
Q2 | USD 14 M | Venta |
59,353
-174,171
| -75% | -USD 35.4 M | ﹤0.01% | 2261 |
|
|
2022
Q1 | USD 41.9 M | Compra |
233,524
+114,607
| +96% | +USD 21.8 M | 0.01% | 1246 |
|
|
2021
Q4 | USD 25.7 M | Venta |
118,917
-202,582
| -63% | -USD 39.8 M | 0.01% | 1748 |
|
|
2021
Q3 | USD 59.3 M | Compra |
321,499
+82,426
| +34% | +USD 16.2 M | 0.01% | 995 |
|
|
2021
Q2 | USD 42.9 M | Venta |
239,073
-80,538
| -25% | -USD 15.3 M | 0.01% | 1262 |
|
|
2021
Q1 | USD 53.5 M | Venta |
319,611
-412,397
| -56% | -USD 68.8 M | 0.01% | 999 |
|
|
2020
Q4 | USD 111 M | Compra |
732,008
+103,306
| +16% | +USD 13.6 M | 0.03% | 494 |
|
|
2020
Q3 | USD 63.5 M | Venta |
628,702
-250,889
| -29% | -USD 27.5 M | 0.02% | 702 |
|
|
2020
Q2 | USD 106 M | Venta |
879,591
-525,343
| -37% | -USD 59.1 M | 0.04% | 376 |
|
|
2020
Q1 | USD 133 M | Compra |
1,404,934
+173,427
| +14% | +USD 16.5 M | 0.06% | 238 |
|
|
2019
Q4 | USD 108 M | Venta |
1,231,507
-228,098
| -16% | -USD 20.1 M | 0.05% | 356 |
|
|
2019
Q3 | USD 116 M | Compra |
1,459,605
+771,704
| +112% | +USD 62.1 M | 0.05% | 340 |
|
|
2019
Q2 | USD 53.7 M | Compra |
687,901
+683,034
| +14,034% | +USD 63.9 M | 0.02% | 683 |
|
|
2019
Q1 | USD 571 k | Venta |
4,867
-21,669
| -82% | -USD 2.52 M | ﹤0.01% | 6579 |
|
|
2018
Q4 | USD 2.89 M | Venta |
26,536
-74,392
| -74% | -USD 8.63 M | ﹤0.01% | 3584 |
|
|
2018
Q3 | USD 12.9 M | Compra |
100,928
+10,481
| +12% | +USD 1.3 M | 0.01% | 1820 |
|
|
2018
Q2 | USD 10.2 M | Venta |
90,447
-60,851
| -40% | -USD 6.69 M | 0.01% | 1900 |
|
|
2018
Q1 | USD 17 M | Compra |
151,298
+130,068
| +613% | +USD 16.5 M | 0.01% | 1264 |
|
|
2017
Q4 | USD 3.14 M | Venta |
21,230
-56,198
| -73% | -USD 7.14 M | ﹤0.01% | 3040 |
|
|
2017
Q3 | USD 9.07 M | Compra |
77,428
+48,948
| +172% | +USD 6.25 M | 0.01% | 1691 |
|
|
2017
Q2 | USD 3.7 M | Venta |
28,480
-8,443
| -23% | -USD 1.05 M | ﹤0.01% | 2451 |
|
|
2017
Q1 | USD 5 M | Venta |
36,923
-2,809
| -7% | -USD 426 k | ﹤0.01% | 2045 |
|
|
2016
Q4 | USD 5.7 M | Venta |
39,732
-53,071
| -57% | -USD 6.78 M | 0.01% | 1858 |
|
|
2016
Q3 | USD 11 M | Compra |
92,803
+78,668
| +557% | +USD 9.45 M | 0.01% | 1280 |
|
|
2016
Q2 | USD 1.5 M | Venta |
14,135
-231,390
| -94% | -USD 25.8 M | ﹤0.01% | 3145 |
|
|
2016
Q1 | USD 27.4 M | Compra |
245,525
+233,485
| +1,939% | +USD 29.5 M | 0.03% | 574 |
|
|
2015
Q4 | USD 1.89 M | Venta |
12,040
-75,316
| -86% | -USD 11 M | ﹤0.01% | 2896 |
|
|
2015
Q3 | USD 11.5 M | Compra |
87,356
+61,521
| +238% | +USD 9.9 M | 0.01% | 1272 |
|
|
2015
Q2 | USD 4.49 M | Compra |
25,835
+24,789
| +2,370% | +USD 4.46 M | ﹤0.01% | 2220 |
|
|
2015
Q1 | USD 180 k | Venta |
1,046
-668,097
| -100% | -USD 102 M | ﹤0.01% | 6459 |
|
|
2014
Q4 | USD 86.6 M | Compra |
669,143
+117,749
| +21% | +USD 15.2 M | 0.09% | 243 |
|
|
2014
Q3 | USD 70.9 M | Compra |
551,394
+491,540
| +821% | +USD 50.7 M | 0.07% | 279 |
|
|
2014
Q2 | USD 5.3 M | Compra |
59,854
+54,427
| +1,003% | +USD 5.23 M | 0.01% | 1820 |
|
|
2014
Q1 | USD 510 k | Venta |
5,427
-13,786
| -72% | -USD 1.41 M | ﹤0.01% | 4446 |
|
|
2013
Q4 | USD 2.17 M | Venta |
19,213
-7,733
| -29% | -USD 697 k | ﹤0.01% | 2473 |
|
|
2013
Q3 | USD 2.12 M | Compra |
26,946
+18,377
| +214% | +USD 1.34 M | ﹤0.01% | 2359 |
|
|
2013
Q2 | USD 564 k | Sin cambios |
8,569
| – | – | ﹤0.01% | 3714 |
|
Otros fondos que tienen UTHR en su portafolio
Posición de Ken Griffin en UTHR: resumen de T3 2026
Ken Griffin aumentó su participación en United Therapeutics (UTHR) en 205% durante T3 2026, al comprar aproximadamente USD 323 M y elevar la posición a 928,464 acciones con un valor de USD 503 M. La posición representa 0.06% del portafolio y ocupa el puesto #239.
Ken Griffin reportó por primera vez una posición en UTHR en T2 2013 y desde entonces la ha mantenido en 52 trimestres. Al cierre de T3 2026, 848 fondos que sigue Wall St. Rank mantienen una posición en UTHR.
- Al cierre de T3 2026, Ken Griffin tenía 928,464 acciones de United Therapeutics con un valor de USD 503 M.
- Ken Griffin compró 623,772 acciones de United Therapeutics en T3 2026, por un monto estimado de USD 323 M.
- United Therapeutics representó el 0.06% del portafolio de Ken Griffin en T3 2026 y fue su posición número 239.
- Ken Griffin reportó por primera vez una posición en United Therapeutics en T2 2013 y desde entonces la ha mantenido en 52 trimestres.
- Al cierre de T3 2026, 848 fondos que sigue Wall St. Rank tenían United Therapeutics en su portafolio.
Según el informe 13F de Citadel Advisors correspondiente a T3 2026, presentado el 16 nov 2026.